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Introduction
Beyond simple polypectomy, endoscopic resection of upper
gastrointestinal tract (UGIT) mucosal and submucosal lesions
is conventionally done using either endoscopic mucosal resec-
tion (EMR) or endoscopic submucosal dissection (ESD), and less
frequently by submucosal tunneling endoscopic resection
(STER) or endoscopic full-thickness resection (EFTR) [1]. With
appropriate case selection, these techniques are associated
with comparable outcomes and lower morbidity when compar-
ed to surgical resection [2, 3]. Compared with EMR, ESD results
in higher en-bloc and R0 (complete resection) rates achieving
higher curative resection with lower recurrence rates [4]. How-
ever, ESD is associated with higher rates of adverse events (AEs)
including bleeding and perforation, particularly with duodenal
lesions, is technically complex, and takes longer to perform. In
addition, ESD becomes technically challenging in cases where
prior treatment leads to submucosal fibrosis.
EFTR using the Full-Thickness Resection Device (FTRD; Oves-
co Endoscopy, Tübingen, Germany) is a novel method for resec-
tion of mucosal and submucosal lesions less than 3 cm in size.
The FTRD consists of a special over-the -scope clip (OTSC) with
an integrated snare and a separate tissue grasper designed for
achieving a non-exposure full-thickness resection of the target
lesion. Compared with conventional endoscopic resection tech-
niques, the FTRD has potential for decreasing the procedure
time and rate of complications, especially perforation, as well
as providing an option for resection of non-lifting or previously
incompletely treated lesions. Published data on use of the FTRD
for colonic lesions show a favorable safety profile and efficacy
[5–8], but the available evidence for its use in UGIT is limited
to small single-center case series [9, 10]. We present the first
international multicenter study of safety and efficacy of FTRD
for resection of UGIT lesions.
Patients and methods
This was an international multicenter retrospective study, in-
cluding patients who had endoscopic resection of an UGIT le-
sion using the FTRD. Collaborators were invited to share their
data on the safety and efficacy of using FTRD for UGIT lesions.
Data from procedures performed between January 2017 and
February 2019 were included in the study. For all procedures,
information was provided to patients regarding FTRD proce-
dure as a new option for management of their problem, its pos-
sible harms and potential benefits (e. g. lower expected risk of
perforation, and shorter duration of procedure, potential to
avoid regular surveillance procedures, or surgery), and alterna-
tive treatment options (e. g. ESD, or a surveillance program).
Subsequently, written informed consent was obtained from all
patients. This study followed the guidelines of the 1975 Decla-
ration of Helsinki. The study protocol was reviewed and ap-
proved by the institutional review board at each study center,
as well as the study coordinating center (IRBs 1804019146;
1701017930).
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Background and study aims The Full-Thickness Resec-
tion Device (FTRD) provides a novel treatment option for le-
sions not amenable to conventional endoscopic resection
techniques. There are limited data on the efficacy and safe-
ty of FTRD for resection of upper gastrointestinal tract (GIT)
lesions.
Patients and methods This was an international multi-
center retrospective study, including patients who had an
endoscopic resection of an upper GIT lesion using the
FTRD between January 2017 and February 2019.
Results Fifty-six patients from 13 centers were included.
The most common lesions were mesenchymal neoplasms
(n=23, 41%), adenomas (n =7, 13%), and hamartomas (n
=6, 11%). Eighty-four percent of lesions were located in
the stomach, and 14% in the duodenum. The average size
of lesions was 14mm (range 3 to 33mm). Deployment of
the FTRD was technically successful in 93% of patients (n=
52) leading to complete and partial resection in 43 (77%)
and 9 (16%) patients, respectively. Overall, the FTRD led to
negative histological margins (R0 resection) in 38 (68%) of
patients. A total of 12 (21%) mild or moderate adverse
events (AEs) were reported. Follow-up endoscopy was per-
formed in 31 patients (55%), on average 88 days after the
procedure (IQR 68–138 days). Of these, 30 patients (97%)
did not have any residual or recurrent lesion on endoscopic
examination and biopsy, with residual adenoma in one pa-
tient (3%).
Conclusions Our results suggest a high technical success
rate and an acceptable histologically complete resection
rate, with a low risk of AEs and early recurrence for FTRD re-
section of upper GIT lesions.
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Outcomes
The primary endpoints of this study were:
1. Technical success: Complete success was defined as reach-
ing the target lesion with the FTRD, correct application of
the FTRD clip on the lesion and immediate resection with the
integrated snare and complete en bloc endoscopic resec-
tion. Complete en bloc endoscopic resection was defined as
absence of macroscopic evidence of residual lesion after
FTRD use as judged by the endoscopist. Partial success was
defined as reaching the target lesion with the FTRD, correct
application of the FTRD clip on the lesion and immediate re-
section with the integrated snare but partial endoscopic re-
section with positive macroscopic margins [5, 10]. The pro-
cedure was considered incomplete if the target lesion could
not be reached with the FTRD device or if the target lesion
was reached but the endoscopist decided against deploying
the FTRD due to lesion characteristics (e. g. device could not
be oriented properly due to the anatomy, the lesion could
not be accommodated in the cap, or the lesion could not be
retracted with tissue grasper). Device failure was defined as
over-the-scope clip (OTSC), tissue grasper, or integrated
snare malfunction in any way leading to failure of the FTRD
performance.
2. Histological margin: R0 resection was defined as histologi-
cally-complete resection with negative lateral and deep re-
section margins. R1 resection was defined as histologically
incomplete resection with microscopic residual pathology at
resection margins, and Rx resection was defined as indeter-
minate histological margins when the resection margins
could not be adequately examined by pathologist. Histopa-
thological examination of the resected specimens was per-
formed locally at each study center. Subgroup analysis for
primary endpoints was performed to evaluate technical
success and histological resection margins in a subset of
patients with only subepithelial lesions (SEL).
Secondary endpoints of this study were:
1. immediate and delayed procedure-related adverse events
(as defined below),
2. procedure time, and
3. risk of residual or recurrent lesions on follow-up endoscopy
Immediate adverse events (AEs) were defined as those which
occurred and were diagnosed before finishing the index endos-
copy session, corresponding to intra-procedure AE in the ASGE
lexicon [11]. Any AE that occurred or was diagnosed afterwards
was defined as a delayed AE, corresponding to post-procedure
and late AEs in the ASGE lexicon. Minor immediate bleeding was
defined as bleeding that required no intervention beyond
endoscopic hemostasis, and major immediate bleeding was de-
fined as bleeding that required any additional intervention be-
yond endoscopic hemostasis (i. e. blood or blood product trans-
fusion, vasopressors, prolonged admission, and treatment by
interventional radiology or surgery). Minor delayed bleeding
was defined as bleeding that required no intervention beyond
observation and stopped spontaneously, and major delayed
bleeding was defined as bleeding that required any interven-
tion (i. e. repeat endoscopy for hemostasis, blood or blood
product transfusion, vasopressors, prolonged admission, and
treatment by interventional radiology or surgery). Minor bleed-
ing corresponded to a mild AE, and major bleeding a moderate
to severe AE in the ASGE lexicon. Data were also collected on
other AEs including perforation, iatrogenic stricture, injury to
adjacent organs, leakage, infection (e. g. peritonitis, bactere-
mia), or need for surgery. For patients with follow up, endos-
copy data were collected on the duration of follow-up, pres-
ence of residual or recurrent lesions, pathology results, and
need for repeat intervention.
Data management and statistical analysis
A universal data collection instrument including detailed pa-
tient and lesion characteristics as well as outcome definitions
was designed at the study coordinating centers (New York-
Presbyterian Hospital, Weill Cornell Medicine, New York, and
Johns Hopkins Hospital, Baltimore, Maryland, United States)
and was sent to collaborators to ensure consistency across
study centers. De-identified patient data were collected using
these instruments, and analyzed centrally (NewYork-Presbyter-
ian Hospital, Weill Cornell Medicine, New York). Data were col-
lected on patient demographics, their pre-procedure American
Society of Anesthesiologists physical status classification (ASA
class) [12], Charlson comorbidity index (CCI) [13], and use of
steroids and immunosuppressive and antithrombotic medica-
tions. Total procedure time was measured from the insertion
of the first endoscope until the withdrawal of the last endo-
scope (more than one endoscope was needed in most cases).
Summary statistics are presented as mean (SD), and median
(IQR), and Chi-squared test, Fisher's exact test, or logistic re-
gression was used to analyze categorical data. All tests are 2-
tailed with an alpha of 0.05.
Full-Thickness Resection Device (FTRD)
The FTRD (Ovesco Endoscopy, Tübingen, Germany) is an inte-
grated system originally designed and approved for full-thick-
ness resection in the colon, which consists of a transparent cap
(outer diameter of 21mm) with a modified OTSC provided with
a tissue grasper and an integrated hot snare located at the rim
of the transparent cap with the handle of the snare running on
the outer surface of the endoscope under a transparent plastic
sheath. This system can be used with flexible endoscopes with a
diameter of 11.5 to 13.2mm and a working channel diameter of
at least 3.2mm. After marking the target lesion with the elec-
trocautery probe included in the FTRD kit, the endoscope is re-
moved from the patient, and the FTRD is mounted on an endo-
scope (a small-caliber colonoscope or a double-channel thera-
peutic endoscope). In many cases, and as judged necessary by
the endoscopist according to the patient's anatomy, bougie or
balloon dilation of the esophagus especially at the lower esoph-
ageal sphincter in preparation for subsequent passage of the
large device cap (21mm, or 60 Fr) is performed before the
endoscope mounted with FTRD is reinserted and advanced to
the target lesion. The snare is then connected to an electrosur-
gical generator. Subsequently the target lesion is grasped using
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the tissue grasper forceps and retracted into the transparent
cap where the tissue grasper remains fixed in position. After
the OTSC clip is deployed at the base of the target lesion and
the integrated snare is immediately closed just above the clip,
a cutting current is applied to complete the resection (▶Fig. 1,
▶Video 1). Finally, the endoscope is removed with the resected
specimen within the transparent cap and the specimen is then
pinned out on a mounting board and fixed in formaldehyde. An
endoscope is then reinserted to examine the site of the resec-
tion for signs of incomplete resection or complications such as
bleeding, or perforation. Hospital admission after the proce-
dure was at the discretion of the endoscopist.
Results
Patient and lesion characteristics
Between January 2017 and February 2019, a total of 56 patients
underwent FTRD resection for UGI tract lesions across 13 study
centers and were included (▶Table 1). Patients had a mean age
of 61±14 years, and 82% of them were ASA class 1 or 2 (▶Ta-
ble 2). Ten patients were on antithrombotics before the proce-
dure: six patients on aspirin, two patients on warfarin, and one
patient each on a P2Y12 inhibitor, and dual antiplatelet ther-
apy. Aspirin was continued for four patients but was stopped
in two before the procedure, and the remaining antithrombotic
medications were held before the procedure. One patient each
was on systemic steroids and immunosuppressive therapy be-
fore the procedure. Patients had a mean CCI of 3.5 before the
procedure with four (7%) having a diagnosis of end-stage renal
disease, two patients with cirrhosis, ten (18%) patients with
diabetes, seven (13%) with congestive heart failure and coron-
ary artery disease, and nine (16%) with malignancy.
The majority of the FTRDs procedures were performed in the
gastric antrum (n=21, 38%) followed by the gastric body (n =
15, 27%), gastric cardia and fundus (n =11, 19%), duodenum
(n=8, 14%), and esophagus (n =1, 2%). The most common
pre-procedural indications (▶Table 3) were initial resection of
mesenchymal neoplasms including gastrointestinal stromal tu-
mor, GIST, (n =23, 41%), diagnostic full-thickness biopsy (n =
▶ Fig. 1 Endoscopic full-thickness resection of 13mm gastrointestinal stromal tumor using Full-Thickness Resection Device (FTRD). a Initially,
a gastroscope fitted with a transparent cap was advanced to the stomach for examining the lesion. b After marking the margins of the lesions
using FTRD marking probe, the gastroscope was removed and replaced with a double-channel therapeutic endoscope fitted with the FTRD
device and advanced back to the gastric fundus. c,d Using the FTRD tissue grasper, the submucosal lesion was carefully grasped and pulled into
the transparent cap until the marked edges are visualized within the cap. e The integrated over-the-scope clip is then deployed at the base of
the target lesion and the integrated snare is immediately closed just above the clip and the resection is completed by applying cutting current.
f Endoscopic view of the resection site and the deployed clip following the FTRD resection.
Video 1 Endoscopic full-thickness resection using FTRD
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10, 18%), initial resection of adenocarcinoma (n=5, 9%), initial
resection of neuroendocrine tumor (n=5, 9%), resection of re-
sidual or recurrent adenoma (n=4, 7%), resection of residual or
recurrent neuroendocrine tumor (n =4, 7%), resection of resi-
dual or recurrent mesenchymal neoplasms including GIST (n =
3, 5%), and initial resection of adenoma (n=2, 4%). For 39% of
lesions the index FTRD resection was the first diagnostic or
therapeutic intervention, and for 78% of the lesions it was the
first therapeutic intervention (▶Table 2). Twenty-two lesions
(39%) were biopsied before FTRD resection. Four patients with
pre-procedure diagnosis of recurrent or residual neuroendo-
crine tumor had undergone EMR or ESD (complete endoscopic
resection but positive histological margins reported in all cases)
between 3 and 5 months before the FTRD procedure and the fi-
nal pathologies after FTRD resection showed normal or scar tis-
sue. Three patients with pre-procedure diagnosis of residual
adenomas had undergone partial resection (hot snare, EMR,
and ESD) between one and three months before FTRD resection
and their final pathologies showed tubular adenoma. Two pa-
tients with pre-procedure diagnoses of residual mesenchymal
▶Table 1 Distribution of FTRD procedures across study centers.
Study center FTRD, n=56
Center 1: Ulm, Germany 15 (27)
Center 2: Freiburg, Germany 14 (25)
Center 3: Seattle, USA  5 (9)
Center 4: Baltimore, USA  4 (7)
Center 5: Danville, USA  3 (5)
Center 6: Irvine, USA  3 (5)
Center 7: Jackson, USA  3 (5)
Center 8: New York, USA  2 (4)
Center 9: Zurich, Switzerland  2 (4)
Center 10: Seattle, USA  2 (4)
Center 11: New York, USA  1 (2)
Center 12: Scottsdale, USA  1 (2)
Center 13: Tübingen, Germany  1 (2)
FTRD, full-thickness resection device
▶Table 2 Patient and lesion characteristics of FTRD for upper gastro-
intestinal tract lesions.
Total number of FTRDs 56
Age, mean (SD) 61 (14)
Female, n (%) 26 (46)
ASA category, n (%)
▪ 1 18 (32)
▪ 2 28 (50)
▪ 3  9 (16)
▪ 4  1 (2)
Charlson comorbiditiy index, mean (range)  3.5 (0–9)
Antithrombotic use1, n (%)
▪ None 46 (82)
▪ Aspirin  6 (10)
▪ P2Y12 inhibitor  1 (2)
▪ Aspirin plus P2Y12 inhibitor  1 (2)
▪ Warfarin  2 (4)
FTRD location, n (%)
▪ Esophagus  1 (2)
▪ Cardia/Fundus 11 (19)
▪ Stomach body 15 (27)
▪ Antrum 21 (38)
▪ Duodenum  8 (14)
▶Table 2 (Continuation)
Endosonographic layer of origin, n (%)
▪ Mucosa 13 (23)
▪ Submucosa 23 (41)
▪ Muscularis Propria 17 (31)
▪ Unknown  3 (5)
Previous intervention, n (%)
▪ None 22 (39)
▪ Biopsy 22 (39)
▪ Hot snare resection  1 (2)
▪ EMR  9 (16)
▪ ESD  2 (4)
Result of previous intervention, n (%)
▪ Partial resection with positive macroscopic
margin
 5 (9)
▪ Complete resection with positive microscopic
margin
 4 (7)
▪ Failed prior resection  2 (4)
▪ Complete resection with recurrence  1 (2)
▪ No previous attempt at resection 44 (78)
Non-lifting sign, n (%)
▪ Not tested 49 (87)
▪ Negative, could be completely lifted  2 (4)
▪ Positive, could not be lifted  5 (9)
FTRD, full-thickness resection device; EMR, endoscopic mucosal resection;
ESD, endoscopic submucosal dissection
1 Aspirin was stopped for two patients before the procedure; P2Y12 inhibitor
and Warfarin were stopped before the procedure.
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neoplasm had undergone partial resection with EMR and cap-
assisted EMR 2 to 4 years before the FTRD resection and their
final pathologies revealed mesenchymal neoplasm (▶Table 3,
▶Fig. 2).
Mean lesion size estimated before FTRD was 12±4mm with
a range of 3mm to maximum of 20mm. Endoscopic Ultrasound
(EUS) was performed for 53 (95%) of lesions before resection
and showed the layer of origin to be submucosa, muscularis
propria, and mucosa in 41%, 31%, and 23% of the lesions,
respectively. Lifting of the lesion with submucosal injection
was attempted in only seven lesions before resection and five
of them could not be lifted.
Outcomes
Technical success
FTRD resection led to complete technical success in 43 patients
(77%), and partial success in another nine patients (16%).
There were two incomplete procedures (4%): The target lesion
could not be reached with the FTRD device for a GIST in the gas-
tric fundus, and for a GIST in the antrum the target lesion was
reached but the FTRD device was not deployed as the lesion
could not be retracted into the cap (▶Table 3; ▶Table4). There
were two cases of device failure. In both the integrated snare
snapped after deployment of the clip, and the lesion was re-
sected above the clip with either a separate snare or an endo-
scopic knife. Of the nine patients who had partial FTRD resec-
tion, four underwent additional endoscopic intervention during
the same session with forceps avulsion and hot snare resection.
There was a trend toward association between the size of the
FTRD resection specimen and technical success rate as proce-
dures that led to the resection of a larger specimen were more
likely to achieve complete technical success (OR 1.12, 95% CI
0.99–1.25, P=0.05). However, the size of the target lesion itself
was not significantly associated with technical success rate (P >
0.05). The number of FTRD procedures performed in an institu-
tion was not significantly associated with the technical success
rate (P=0.827). Lesion location, layer of origin, Paris classifica-
tion, pathology, or previous intervention were not associated
with the technical success rate (P>0.05).
The majority (62%) of FTRD procedures were performed
under propofol sedation, 36% with general anesthesia, and 2%
under conscious sedation. The majority of procedures (n =29,
52%) were performed without antibiotic prophylaxis, while 21
▶Table 3 Pre-procedure indication, final pathology, and prior treatment history of the lesions.
Pre-procedure indication Final Pathology Prior treatment
Mesenchymal neoplasm including GIST, initial resection, n = 23 Mesenchymal neoplasm, other than GIST, n = 10
GIST, n =7
Hamartomatous polyp, n = 2
Ectopic pancreas, n = 2
Normal tissue, n = 1
Unavailable, n = 1
NA
Full-thickness biopsy, n = 10 Hamartomatous polyp, n = 4
GIST, n = 2
Adenoma with HGD, n = 1
Hyperplastic polyp, n = 1
Mesenchymal neoplasm, other than GIST, n = 1
Scar tissue, n = 1 EMR
Adenocarcinoma, intial resection, n = 5 Adenocarcinoma, n =3
Tubular adenoma, n =1
Scar tissue1, n = 1
NA1
NET, initial resection, n = 5 NET, n = 4
Hyperplastic polyp, n = 1
NA
NET, residual, n = 4 Normal or scar tissue, n = 4 EMR, ESD
Adenoma, residual, n = 4 Tubular adenoma, n =3 Hot snare, EMR, ESD
Scar tissue, n = 1 EMR
Mesenchymal neoplasm including GIST, residual or recurrent, n = 3 Mesenchymal neoplasm, other than GIST, n = 3 EMR, Cap-assisted EMR
Adenoma, initial resection, n = 2 Tubular adenoma, n =1
Sessile Serrated Adenoma, n =1
NA
GIST, gastrointestinal stromal tumor; FTRD, full-thickness resection device; NET, neuroendocrine tumor; EMR, endoscopic mucosal resection; ESD, endoscopic sub-
mucosal dissection
1 Patient underwent a biopsy with jumbo forceps before the FTRD, which removed the adenocarcinoma completely, and the final FTRD pathology showed only scar
tissue with surrounding intestinal metaplasia.
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▶ Fig. 2 Association between indication and final pathology of upper gastrointestinal tract FTRD resection.
▶Table 4 Detailed description of the study outcomes.
Technical success1 N= 56 Description
Complete success n =43 complete en bloc endoscopic resection
Partial success n =9 partial endoscopic resection with positive macroscopic margins
Incomplete procedure n =2 GIST in gastric fundus: The target lesion could not be reached with the FTRD device
GIST in the antrum: the lesion could not be retracted into the cap
Device failure n =2 For both: the integrated snare snapped after deployment of the clip, and the lesion was resected above the
clip with a separate instrument
Histological margin N= 56 Description
R0 n =38 Histologically-complete resection with negative lateral and deep resection margins
R1 n =10 4 cases of complete en bloc resection with positive lateral margins
6 cases of partial resection with positive lateral margins
Rx n =2 1 case of complete en bloc resection with indeterminate margins
1 case of partial resection with indeterminate margins
Missing n =2 2 cases for whom data for the histological margin were missing
Not applicable n =4 4 cases of incomplete procedure or device failure described above, without any tissue resection
GIST, gastrointestinal stromal tumor; FTRD, full-thickness resection device
1 Complete technical success: defined as reaching the target lesion with the FTRD, correct application of the FTRD clip on the lesion and immediate resection with the
integrated snare AND complete en bloc endoscopic resection. Partial success was defined as reaching the target lesion with the FTRD, correct application of the
FTRD clip on the lesion and immediate resection with the integrated snare but partial endoscopic resection with positive macroscopic margins Procedure was
considered incomplete if the target lesion could not be reached with the FTRD device or if the target lesion was reached but the endoscopist decided against de-
ploying the FTRD due to lesion characteristics. Device failure was defined as over-the-scope clip, tissue grasper, or integrated snare malfunction in any way leading
to failure of the FTRD. R0 resection was defined as histologically-complete resection with negative lateral and deep resection margins. R1 resection was defined as
histologically incomplete resection with microscopic residual pathology at resection margins, and Rx resection was defined as indeterminate histological margins
when the resection margins could not be adequately examined by pathologist.
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patients (37%) received a single intravenous dose of pre-proce-
dural antibiotic, and six (11%) received combined pre- and
post-procedural prophylactic antibiotics. Mean total procedure
time was 42±16 minutes with a range of 18 to 90 minutes.
Histological margin of resection
Of the 43 patients with complete technical success, 38 (88%)
had negative histological margins indicating an R0 resection
yielding an overall rate of 68% R0 resections of all the per-
formed FTRD resections. Four (10%) patients with complete
en bloc resection had R1 resection with positive histological
margin, and one (2%) had an indeterminate (Rx) resection mar-
gin. Of the nine patients with partial technical success, six had
R1 resection with positive histological margin, one had an Rx or
indeterminate resection margin, and the data for the histologi-
cal margin for other two patients was missing (▶Table 4). The
mean diameter of resected specimen was 15 ± 9mm, ranging
from 3mm to 35mm, with 10% of the resected specimens hav-
ing a diameter of 30mm or greater on pathologic exam. The
mean depth of resected specimen was 6±4mm ranging from
2mm to a maximum 18mm with 10% of the resected speci-
mens having a depth of 14mm or greater on pathologic exam
(▶Table5). Lesions size was inversely associated with probabil-
ity of successful R0 resection (OR=0.85, 95%CI 0.72–0.99, P=
0.038). In fact, the probability of complete R0 resection chan-
ged from 73% in lesions with a diameter < 15mm to only 29%
in lesions with a diameter≥15mm (P=0.034).
Subgroup analysis
Subgroup analysis was performed including only the subepithe-
lial lesions (SELs) to evaluate the technical success rate and his-
tological margin of resection in lesions arising from submucosa
and muscularis propria. There were 27 SELs including Neuroen-
docrine tumors, granular cell tumors, and mesenchymal neo-
plasms including GIST. Thirty-six percent of SELs originated
from muscularis propria, and the remaining 64% originated
from submucosa. FTRD resection led to complete technical
success in 21 patients (78%) with SEL, and partial success in an-
other three patients (11%). There were two incomplete proce-
dures (7.5%) for two gastric GISTs, as described above. There
was one case of device failure due to malfunction the integra-
ted snare as described above. The complete success rate did
not differ significantly between SELs (78%), and the rest of the
of the lesions (73%, P=0.643). Of the 27 patients with SEL, 19
(70%) had negative histological margins indicating an R0 resec-
tion. Five (19%) patients had R1 resection with positive histolo-
gical margin. The R0 resection rate did not differ significantly
between SELs (70%), and the rest of the of the lesions (66%, P
=0.698). The mean diameter of resected SEL specimens was 16
±8mm, ranging from 6mm to 35mm, with 10% of the resected
specimens having a diameter of 30mm or greater on patholog-
ic exam. Mean depth of resected SEL specimens was 9±4mm
ranging from 5mm to a maximum 18mm with 10% of the re-
sected specimens having a depth≥15mm on pathologic exam.
Mean depth of the resected specimens was larger for SELs com-
pared to the mucosal lesions (9mm versus 4mm, P<0.001).
Similar to the overall analysis, the size of the lesion was inverse-
▶Table 5 Procedural details and outcomes of FTRD for upper gastro-
intestinal tract lesions.
Total number of FTRDs 56
Antibiotic prophylaxis, n (%)
▪ None 29 (52)
▪ Single-dose pre-procedural 21 (37)
▪ Pre and post-procedural  6 (11)
Sedation, n (%)
▪ Propofol procedural anesthesia 35 (62)
▪ General anesthesia 20 (36)
▪ Conscious sedation  1 (2)
Procedure time; minutes, mean (range) 42 (18–90)
Diameter of resected lesion (mm), mean (SD) 16 (9)
Diameter of resected lesion (mm), range  3–35
Depth of resected lesion (mm), mean (SD)  6 (4)
Depth of resected lesion (mm), range  2–18
Technical success1, n (%)
▪ Complete success 43 (77)
▪ Partial success  9 (16)
▪ Incomplete procedure  2 (4)
▪ Device failure  2 (4)
Histological margin, n (%)
▪ R0 38 (68)
▪ R1 10 (17)
▪ Rx  2 (4)
▪ Missing  2 (4)
▪ NA (incomplete or failed procedure)  4 (7)
Complications, n (%)
▪ Minor intraprocedural bleeding  4 (7)
▪ Major intraprocedural bleeding  4 (7)
▪ Minor delayed bleeding  2 (4)
▪ Major delayed bleeding  1 (2)
▪ Injury, including adjacent organs  1 (2)
1 Technical success: defined as reaching the target lesion with the FTRD,
correct application of the FTRD clip on the lesion and immediate resection
with the integrated snare AND complete en bloc endoscopic resection.
Partial success was defined as reaching the target lesion with the FTRD,
correct application of the FTRD clip on the lesion and immediate resection
with the integrated snare but partial endoscopic resection with positive
macroscopic margins Procedure was considered incomplete if the target
lesion could not be reached with the FTRD device or if the target lesion was
reached but the endoscopist decided against deploying the FTRD due to
lesion characteristics. Device failure was defined as over-the-scope clip,
tissue grasper, or integrated snare malfunction in any way leading to failure
of the FTRD
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ly associated with the probability of successful R0 resection
(OR=0.67, 95%CI 0.48–0.98, P=0.035) in patients with SEL.
Adverse events
There were a total of 12 (21%) reported AEs. Their severity
based on ASGE Lexicon were classified as mild in seven patients
(12%), and moderate in five patients (9%), without any report-
ed severe AEs [11].
Immediate intraprocedural AEs were reported in nine pa-
tients (16%) (▶Table5): four cases (7%) of immediate minor
bleeding (mild AE), one managed conservatively and three
treated with thermal coagulation; four cases (7%) of immediate
major bleeding needing transfusion and/or pressors (moderate
AE), one managed with thermal coagulation while the remain-
ing three with hemostatic clips; and one case of mucosal/sub-
mucosal injury by the integrated snare to the contralateral lu-
minal wall at gastroesophageal junction that did not result in
perforation or bleeding and was managed conservatively with
two days of observation in hospital (mild AE).
Delayed AEs were reported in three cases: two cases of mi-
nor bleeding 1 and 7 days after the procedure, both managed
conservatively (mild AE), and one case of delayed major bleed-
ing 2 days after the procedure which was managed endoscopi-
cally without need for surgery (moderate AE).
Four patients were taking aspirin at the time of the proce-
dure, but there was no association between aspirin use and
risk of bleeding (P=0.470). Similarly, size of lesion, previous
biopsy or attempted resection, procedure length, and patholo-
gy of the resected lesion or its layer of origin were not associat-
ed with bleeding (P >0.05).
A majority (70%) of the patients were admitted following
the procedure for a median of 3 days after FTRD resection (IQR
2–3 days) with a range of 1 to 6 days post-procedure admission,
while 17 patients (30%) were discharged on the day of the pro-
cedure. The majority (73%) of patients who were admitted
post-procedurally did not have any complications and there
was a strong association between study centers and admitting
patterns with some centers admitting all of their FTRD resec-
tion patients for observation and some centers discharging pa-
tients on the same day. After accounting for the effect of insti-
tutions on admission patterns after the FTRD procedure, com-
plications (early or late) were associated with an increased
chance of admission (P=0.05) but none of the other variables
including previous treatment, location, size, layer of origin,
Paris classification, indication or final pathology were associat-
ed with post-procedural admission (P >0.05).
Follow-up
Patients were followed for a median of 3 months (IQR 1–6
months) after the procedure. There was one death reported
49 days after the procedure due to underlying end-stage heart
failure, deemed not to be related to the procedure itself. Fol-
low-up endoscopy was accomplished in 31 patients (55%), on
average 88 days after FTRD resection (IQR 68–138 days). The
majority of these patients (n =30, 97%) did not have any resi-
dual or recurrent lesion on endoscopic examination and biopsy.
Residual adenoma was found only in one patient who had an in-
itial partial resection of tubular adenoma and was treated suc-
cessfully with endoscopic resection. In 43% the FTRD clip was
still in place during the follow up endoscopy and three patients
had mucosal ulceration at the site of the resection when exam-
ined during the follow up endoscopy without need for endo-
scopic therapy.
Discussion
This study reports indications, outcomes, and safety of the
FTRD for endoscopic full-thickness resection (EFTR) of UGI tract
lesions, using data from early-adopters of this technique in Eur-
ope and United States. The most frequent indication for use of
the FTRD in this cohort was resection of mesenchymal neo-
plasms, including GIST, most commonly located in the stom-
ach. Although the FTRD is currently approved only for use in
the lower gastrointestinal tract lesions, our results suggest an
acceptable technical and clinical success rate and safety profile
for using FTRD in the foregut, making it a potential alternative
to other resection techniques such as ESD.
Previous studies have evaluated the FTRD for resection of
colonic lesions. In the most comprehensive prospective report
to date, Schmidt et al reported the results of FTRD resection in
181 patients with colonic lesions including subepithelial lesions
(SEL). They reported a technical success rate of 89.5% with
complete en bloc resection, and an R0 resection rate of 76.9%.
The AE rate was reported at 9.9% with 2.2% need for emergen-
cy surgery, and recurrent/residual tumor seen in 15.3% of cases
at 3 months’ follow-up [5]. They reported bleeding as a moder-
ate AE in four (2.2%), all of which happened after the index
FTRD session (Days 1 to 3), and were managed endoscopically
without need for surgery. They also reported perforation in six
(3.3%), five of which occurred because the clip was not de-
ployed properly leading to an immediate perforation. In con-
trast, reports on use of the FTRD device for resection of UGI
tract lesions are more limited. In the largest case series using
the FTRD device for resection of duodenal lesions, Bauder et
al. reported a series of 20 patients (13 adenomas, and 5 SELs),
with an 85% technical success rate and overall R0 resection rate
of 60%. They reported minor bleeding rate of 16%, but no ma-
jor bleeding or perforations [10]. Compared with these results,
we report a technical success rate of 77% and an R0 resection
rate of 68%, comparable to the previously reported results in
the duodenum. Similarly, there were no perforations in our
study, and the most common adverse event was mild or mod-
erate procedure-related bleeding with a rate of 19.6%, all man-
aged successfully either conservatively or endoscopically. It
should be noted that although the size of lesions in our report
is similar to the above-mentioned series of duodenal lesions
(average of 16 vs 17mm), the type of lesions is different with
SELs comprising 72% of lesions in our report compared with
only 25% in the report by Bauder et al, possibly accounting for
the difference in the en bloc resection rates. More recently, Me-
ier et al. (RESECT trial) have reported results of using a modified
version of the FTRD (Gastroduodenal or gFTRD, Ovesco Endos-
copy, Tübingen, Germany) for resection of gastric SELs in 29 pa-
tients [14]. Compared with the colonic FTRD device, gFTRD has
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a slightly narrower cap (19.5 vs 21mm for colonic FTRD) and
can be used with endoscopes with a smaller diameter (10.5 vs
11.5mm for colonic FTRD).
Furthermore, the device comes with an insertion balloon to
facilitate its passage through the UGI tract. This prospective
study was limited to gastric SELs≤15mm (median lesion size
11mm) and reports a technical success rate of 89.7% for en
bloc resection, and R0 resection rate of 76%, with immediate
minor bleeding as the only observed complication seen in 31%
of patients, which was managed endoscopically in all cases.
Given the significant difference in lesion size (median of 11 vs
17mm in our study), it is unclear how much of the observed dif-
ference in the technical success and R0 resection rates (89.5%
vs 77% and 76% vs 68%, respectively) is attributable to the de-
sign of the new device or expertise of the study centers. Com-
bining the above results, the available data suggest that using
FTRD for resection of UGI tract lesions, including SELs, can
lead to similar success rates compared with colonic FTRD, while
potentially associated with lower rate of severe AEs, given that
the most common, and almost exclusive, reported AE has been
mild to moderate procedure-related bleeding. The higher rate
of immediate mild bleeding but fewer perforations compared
with significantly lower rates of immediate bleeding but higher
perforation rate for FTRD in the colon is an interesting finding
[5]. This might be explained on the basis of thicker wall and bet-
ter blood supply of the stomach compared to the colon with a
protective effect against perforation but increasing the likeli-
hood of procedure-related bleeding.
In our cohort, the most common final pathology was me-
senchymal neoplasms including GIST (n=23, 41% of lesions),
mainly located in the stomach, which is compatible with the
known epidemiology of gastric GIST as the most common sub-
epithelial lesion (SEL) in the GI tract [15]. Although all GIST have
some malignant potential, only about one fourth of gastric
GISTs are malignant at the time of diagnosis [16]. Available di-
agnostic and prognostic tools such as size and location of the
lesion, endoscopic findings, EUS findings and results of EUS-
guided biopsy can help make accurate diagnosis and risk strati-
fy before decision for resection is made for SELs of upper gas-
trointestinal tract, but these tools have suboptimal accuracy
for mesenchymal neoplasms including GIST, as well as for SELs
in general [17–21]. Therefore, considering the potentially lim-
ited histological data available from conventional, “bite-on-
bite,” or even EUS-guided biopsies [22], en bloc resection of
UGI tract SELs represents the most accurate diagnostic tool as
well as a potentially curative treatment, especially as some
guidelines suggest resection even for small GISTs (i. e. < 2 cm)
as there is a potential for progression and metastasis [23].
Although there is a lack of direct comparison with surgical
resection, endoscopic resection of UGI tract SELs, while remain-
ing a controversial option, has been shown to be effective and
safe [24, 25]. Submucosal dissection and resection including
ESD and STER can achieve en bloc endoscopic resection of
SELs. However, compared with FTRD, they are more technically
challenging, more time consuming, and at least in the case of
ESD, associated with high risks of complications such as per-
foration. For ESD of gastric SELs, perforation rates as high as
14% have been reported [24] and pooled analysis of the STER
case series has showed a perforation rate of 6% and high rates
of air-leakage [26]. In comparison, there were no cases of per-
foration in our cohort or other case series of UGI tract FTRD for
resection of UGI tract SELs. It should be noted however that al-
most all of the reported complications with ESD and STER are
managed successfully either during the index endoscopic ses-
sion or conservatively afterwards, and do not seem to affect
the final outcome of the procedure. Additionally, the submuco-
sal dissection techniques have the advantage of being able to
treat larger lesions, as FTRD is limited by the size of the device
cap and clip [27].
The effectiveness of using FTRD depends on the ability of
positioning the lesion completely within the device cap prior
to deploying the clip. This in turn depends on lesion size and
mobility, with the latter influenced mostly by anatomic location
and presence of submucosal fibrosis. In our cohort, the largest
size of the resected specimen was 35mm and size of the target
lesion or its location even after multiple sensitivity analyses for
separating duodenal and gastric lesions were not found to be
significantly associated with technical success or R0 resection
rates. Similarly, we did not find an association between history
of prior endoscopic intervention and FTRD outcome. Another
commonly encountered limitation of the FTRD is the size of
the device cap (21mm) which makes traversing the upper and
lower esophageal sphincters and pylorus difficult in some
cases. Many endoscopists use bougie or balloon dilation imme-
diately before passage of the FTRD. In certain cases, the rela-
tively limited flexibility of the device mounted on larger endo-
scopes (typically a slim colonoscope) can also hinder reaching
the target lesion as was the case for a patient in our study in
which the endoscopist was not able to reach the target lesions
located in the fundus.
This study is limited due to its retrospective design with a
limited sample size, leading to possible selection bias and po-
tential for limited power and type II error when assessing the
above presented correlations between different variables and
FTRD outcomes. We also did not have data for follow-up endos-
copy for all the cases, limiting assessment of long-term FTRD
resection outcomes. Therefore, our estimates of recurrence
should be interpreted cautiously. Compared to other available
reports, we were able to gather data on a larger number of pa-
tients and from a variety of early users of the UGI tract FTRD re-
section technique from different centers in the Unites States
and Europe to have a more representative sample of the patient
population and a more accurate estimate on “real-world” FTRD
outcomes and complications.
Conclusion
Our results suggest that FTRD is a relatively safe and effective
option for endoscopic resection of appropriate UGI tract lesions
including SELs, when compared with other available methods.
Two-thirds of our patients had complete histological resection.
Although 21% of patients experienced mild to moderate AEs,
there were no severe or fatal AEs. Endoscopists should carefully
consider different endoluminal resection options based on le-
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sion size and location, and expect to encounter and manage
both immediate and delayed procedure-related bleeding when
planning to use this device.
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